VAUDREUIL-DORION, QUEBEC--(Marketwire - March 31, 2010) - Immunotec Inc. (the "Corporation") (TSX VENTURE:IMM) today announced that pursuant to the Immunotec Stock Option Plan, six directors and two officers were granted options entitling them to acquire up to an aggregate of 225,000 common shares of the Corporation (the "Shares") at an exercise price of $0.375 being the closing price of the Corporation's Shares on the TSX-Venture Exchange on the trading day preceding the grant. These options vest over a three-year period, with one-third (1/3) which vest immediately, and one-third (1/3) which shall vest on each of the first and second anniversaries of the date of the grant. Each option is exercisable, once vested, for a period of five years from the date of the grant.
About Immunotec Inc.
Immunotec is a Network Marketing Company involved in the direct selling of scientifically validated natural health products and dietary supplements. The Company offers a lucrative business opportunity to its independent distributors. This business model provides Immunotec's network of people with an opportunity to earn a steady and recurring income, directly based on their level of involvement and performance. Individual distributors build their business by conveying product information and selling product to customers and by building teams of distributors to expand geographic penetration and market coverage to larger populations of customers.
Headquartered with manufacturing facilities near Montreal, Canada, the Company also subcontracts certain distribution logistics and capacity to support its activities in the United States, Europe and The Caribbean.
The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.
"The TSX Venture does not accept responsibility for the adequacy or accuracy of this release."